Global Sarcoma Drugs Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 1,222.20 Million |
 Market Size (Forecast Year) |
USD 2,435.31 Million |
 CAGR |
% |
| Major Markets Players |
>全球肉瘤药物市场，按类型（血管肉瘤、上皮样肉瘤、脂肪肉瘤、骨肉瘤、软组织肉瘤、卡波西肉瘤、软骨肉瘤、隆突性皮肤纤维肉瘤、平滑肌肉瘤、其他）、药物治疗（化疗、靶向治疗、免疫治疗、其他）、药物类型（品牌、仿制药）、最终用户（医院、专科诊所、家庭医疗保健、其他）、分销渠道（直接招标、医院药房、零售药房、网上药房、其他）划分——行业趋势和预测到 2030 年。
肉瘤药物市场分析及规模
根据美国国家癌症研究所的数据，2019 年美国医生诊断出约 12,750 例软组织肉瘤，其中 5,270 人死于该疾病。然而，治疗和诊断技术的进步以及肉瘤和其他皮肤癌发病率的上升推动了市场的增长。此外，发展中地区对低成本疗法的需求不断增长，为市场带来了增长机会。
Data Bridge Market Research 分析，2022 年肉瘤药物市场规模为 12.222 亿美元，预计到 2030 年将达到 24.3531 亿美元，2023 年至 2030 年预测期内的复合年增长率为 9.00%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。
肉瘤药物市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021（可定制为 2015 - 2020） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
类型（血管肉瘤、上皮样肉瘤、脂肪肉瘤、骨肉瘤、软组织肉瘤、卡波西肉瘤、软骨肉瘤、隆突性皮肤纤维肉瘤、平滑肌肉瘤、其他）、药物疗法（化疗、靶向疗法、免疫疗法、其他）、药物类型（品牌药、仿制药）、最终用户（医院、专科诊所、家庭医疗保健、其他）、分销渠道（直接招标、医院药房、零售药房、网上药房、其他） |
|
覆盖国家 |
北美洲的美国、加拿大和墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、巴西、阿根廷和南美洲其他地区 |
|
涵盖的市场参与者 |
Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Pfizer Inc (U.S.), Mylan N.V. (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany) |
|
Market Opportunities |
|
Market Definition
Sarcoma is a type of cancer that can occur in any part of the body. Sarcoma begins in the bone and soft tissues and then spreads to other parts of the body. Although there are over 50 different types of sarcoma, they can be divided into two categories: soft tissue sarcoma and bone sarcoma, also known as osteosarcoma. Sarcoma is uncommon in adults. According to the American Society of Clinical Oncology, it accounts for about 1% of all adult cancers (ASCO). It is more prevalent in children, accounting for about 15% of all pediatric cancers.
Sarcoma Drugs Market Dynamics
Drivers
- Growing use of immunotherapy for the treatment of sarcoma
Stimulating or boosting the natural defences of a patient's immune system so that it works harder or smarter to find and attack cancer cells. Immunotherapy has recently become an important part of the treatment of certain types of cancer. New immunotherapy treatments and new ways of working with the immune system are being tested and approved at a rapid pace. Immunotherapy is more effective for some cancers than others. During the forecast period, these factors are expected to drive the growth of the sarcoma drugs market.
- Increasing Cancer Prevalence to support Sarcoma Drugs
Cancer has surpassed cardiovascular disease as the world's second leading cause of death. Environmental factors such as tobacco use, urbanization, changing dietary patterns, and an extended post-reproductive lifespan all contribute to this phenomenon. Cancer is a growing burden, according to the World Health Organization (WHO), with the number of new cancer cases expected to rise from 18.1 million in 2018 to 29.4 million by 2040. As a result, rising cancer prevalence is expected to drive demand for global oncology cancer drugs during the forecast period. Furthermore, rising cancer awareness is expected to benefit the sarcoma drugs market in the coming years.
Opportunities
- Possession of a Strong Drug Pipeline to Fuel Sarcoma Drugs
Cancer treatment is evolving at a rapid pace. The R&D pipeline is producing a slew of novel treatments, many of which are frequently combined with other new or existing medications. Many pharmaceutical companies are investing in novel cancer drug research. For instance, Pfizer acquired Array BioPharma in 2019 with the goal of expanding its oncology presence and pipeline, beginning with an approved melanoma combination therapy that is currently in a phase 3 trial for a type of metastatic colorectal cancer. This, combined with an rising preference for biosimilar and biologics entering the market, is expected to propel the sarcoma drugs market forward.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained healthcare professionals who are unaware of the treatment methods for this disease may limit the growth of the global sarcoma drugs market during the forecast period.
This sarcoma drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the sarcoma drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In 2020, Junshi Biosciences, a global biopharmaceutical company, received FDA approval for Orphan Drug designation for toripalimab to treat soft tissue sarcoma. This approval is expected to assist the company in marketing new products and attracting new customers, resulting in increased revenue.
Global Sarcoma Drugs Market Scope
The sarcoma drugs market is segmented on the basis of type, drug therapy, drug type, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Angiosarcoma
- Epithelioid Sarcoma
- Liposarcoma
- Osteosarcoma
- Soft Tissue Sarcoma
- Kaposi's Sarcoma
- Chondrosarcoma
- Dermatofibrosarcoma Protuberans
- Leiomyosarcoma
- Others
Drug Therapy
- Chemotherapy
- Doxorubicin
- Epirubicin
- Ifosfamide
- Eribulin
- Temozolomide
- Methotrexate
- Others
- Targeted therapy
- Olaratumab
- Imatinib
- Pazopanib
- Pexidartinib
- larotrectinib
- Others
- Immunotherapy
- Pembrolizumab
- Others
Drug Type
- Branded
- Lartruvo
- Gleevec
- Votrient
- Tazverik
- Turalio
- Vitrakvi
- keytruda
- Others
- Generic
End-Users
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
Distribution Channel
- Direct Tender
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Sarcoma Drugs Market Regional Analysis/Insights
The sarcoma drugs market is analyzed and market size insights and trends are provided by country, type, drug therapy, drug type, end-users and distribution channel as referenced above.
The countries covered in the sarcoma drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the sarcoma drugs market due to the presence of high healthcare expenditure and favourable reimbursement policies for the treatment.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to constant rise in the incidence of cancer coupled with increased demand for cost-efficient therapeutics.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The sarcoma drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for sarcoma drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the sarcoma drugs market. The data is available for historic period 2011-2021.
Competitive Landscape and Sarcoma Drugs Market Share Analysis
The sarcoma drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to sarcoma drugs market.
Some of the major players operating in the sarcoma drugs market are:
- Johnson & Johnson Private Limited (U.S.)
- Abbott (U.S.)
- AbbVie Inc.（美国）
- Bausch Health Companies Inc.（加拿大）
- 太阳制药工业有限公司 (印度)
- Aurobindo Pharma（印度）
- 鲁冰花（印度）
- Hikma Pharmaceuticals PLC（英国）
- Amneal Pharmaceuticals LLC.（美国）
- 辉瑞公司 (美国)
- Mylan NV（美国）
- 百时美施贵宝公司 (美国)
- 葛兰素史克公司（英国）
- 拜耳公司（德国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
